Hormonal
The dual GLP-1R/GCGR agonist BI 456906 produces clinically meaningful body weight loss (up to 13.8% over 16 weeks) in adults with overweight/obesity, driven by target engagement at both receptors.
BI 456906 is a once-weekly injection for people with overweight or obesity that works by targeting two hormones (GLP-1 and Glucagon). In early studies, it led to significant weight loss (nearly 14% over 4 months). The main side effects are gastrointestinal (nausea, vomiting), which are common but often manageable. It is designed for people who may not achieve sufficient weight loss with single-target therapies.
BI 456906 produced a placebo-corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight/obesity.
Why this rating
Phase I clinical trial in healthy volunteers and overweight/obese adults; safety and efficacy data are present but sample sizes are small (N=24 and N=125) and duration is short (16 weeks).
Source
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist <scp>BI</scp> 456906
Arvid Jungnik et al. · Diabetes Obesity and Metabolism · 2022
DOI 10.1111/dom.14948
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →